Beijing Fulerton BioEngineering

Beijing Fullerton Bioengineering is a Chinese medical technology company specializing in the development and manufacture of in vitro diagnostic (IVD) systems and reagents. The company focuses on automated chemiluminescence immunoassay (CLIA) technology, providing comprehensive solutions for clinical testing in hospitals and laboratories. Its product portfolio includes high-throughput analyzers and a broad range of diagnostic kits for tumor markers, cardiac markers, hormones, and infectious diseases. Acquired by Lepu Medical in 2013, the company operates as a key subsidiary within Lepu's diagnostic division, leveraging integrated R&D and manufacturing capabilities to serve the domestic and international healthcare markets. The company is recognized for its contribution to the localization of high-end immunoassay technology in China.